Healthcare entity
Of the tracked stories, 1 of 2 also mention Bank of America, the most common co-covered peer. The 40-day window averages about 0.4 stories each week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Last mentioned: 18h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Bank of America, the most common co-covered peer. The 40-day window averages about 0.4 stories each week. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. The 5.5 average consequence score is below the beat benchmark of 6 in the same window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Healthcare stories that mention Goldman Sachs, published between July 4, 2026 and August 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 357 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Goldman Sachs. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Ladenburg Thalmann Upgrade
Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
Weiss Ratings Upgrade
Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
Director Insider Purchase
Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
Wall Street Zen Downgrade
Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
Goldman Sachs Initiates Coverage
Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.
Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Source: dailypolitical.com · tickerreport.com
Intuitive Surgical's decision to extend force-feedback tool usage from 6 to 15 uses could accelerate robotic surgery adoption in hospitals, easing supply chain woes and lowering per-procedure costs without sacrificing revenue.
Source: The Motley Fool · James Halley (us)
Goldman Sachs is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
